XORTX Total Liab from 2010 to 2024

XRTX Stock  USD 1.27  0.06  4.96%   
XORTX Therapeutics Total Liabilities yearly trend continues to be fairly stable with very little volatility. Total Liabilities will likely drop to about 784.6 K in 2024. Total Liabilities is the total amount of all liabilities that XORTX Therapeutics has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2014-12-31
Previous Quarter
2.1 M
Current Value
1.7 M
Quarterly Volatility
2.6 M
 
Yuan Drop
 
Covid
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 1 M, Other Operating Expenses of 2.4 M or Total Operating Expenses of 2.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.89. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of XORTX Therapeutics Correlation against competitors.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Latest XORTX Therapeutics' Total Liab Growth Pattern

Below is the plot of the Total Liab of XORTX Therapeutics over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. XORTX Therapeutics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

XORTX Total Liab Regression Statistics

Arithmetic Mean1,137,170
Geometric Mean448,368
Coefficient Of Variation136.42
Mean Deviation989,402
Median784,641
Standard Deviation1,551,272
Sample Variance2.4T
Range5.3M
R-Value0.59
Mean Square Error1.7T
R-Squared0.35
Significance0.02
Slope204,489
Total Sum of Squares33.7T

XORTX Total Liab History

2024784.6 K
2023825.9 K
20225.4 M
20214.2 M
2020M
20191.3 M
2018943.7 K

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Liabilities825.9 K784.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.